Crimean–Congo hemorrhagic fever (CCHF) is a dangerous viral illness spread by ticks and livestock; it can cause sudden fever, organ failure and internal bleeding, and there are no approved vaccines or specific treatments. A new mouse study published in npj Vaccines reports promising results for an experimental vaccine developed by a team that includes Scott Pegan at the University of California, Riverside.
The vaccine uses a virus-like replicon particle. It mimics how a virus enters cells but lacks the genetic material needed to replicate, so it cannot cause infection. The team previously showed one dose could protect animals within three days. The new study measured antibody responses after one or two doses and found antibodies detectable for up to 18 months, an interval the authors say roughly equals several human years. Antibody levels were similar between one- and two-dose groups for about nine months; a booster produced stronger, more stable antibodies and longer protection.
The vaccine focuses on internal viral proteins, especially the N protein, normally hidden inside the virus and important for immunity. Researchers aim to move to large-scale production under Good Manufacturing Practice before human trials. Partners at the CDC are already exploring the platform for other pathogens.
Difficult words
- hemorrhagic — causing severe bleeding inside the body
- replicon — a viral particle that cannot make full copies
- antibody — a blood protein that fights infectionsantibodies
- booster — an extra vaccine dose to increase protection
- platform — a system or method used for development
- pathogen — an organism that causes disease in peoplepathogens
- replicate — to make more copies of itself
- immunity — protection in the body against disease
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- Why might it be important that the vaccine cannot replicate in the body?
- Would you feel more confident about a vaccine that gives detectable antibodies for 18 months? Why or why not?
- How could using the same vaccine platform for different pathogens help public health?
Related articles
Cholera spreads where water and health systems fail
Cholera spread widely in 2024, with 560,823 reported cases and 6,028 deaths. Conflict, climate shocks and damaged water and health services drove outbreaks, while vaccines and better water and sanitation are key to preventing deaths.
Cell transplant may help heart after spinal cord injury
Researchers tested transplanting immature nerve cells into spinal cord injuries in rats. The transplants improved nerve control of circulation — stabilizing resting blood pressure and lowering heart rate — but hormonal responses after injury still rose.
Which childhood food allergies are outgrown?
Many children outgrow milk and egg allergies, while peanut, tree nut, sesame and shellfish allergies often persist. Factors such as IgE levels, allergy severity and genetics affect whether a child becomes tolerant and which treatments help.
Experts call for integrated One Health surveillance linking communities
Experts urge governments to build integrated surveillance systems that link community-level data across human, animal, plant and environmental sectors. A virtual roundtable highlighted research priorities and named integrated surveillance the most urgent need.